Researchers at the Institute of Science Tokyo have developed a pioneering mRNA vaccine targeting pathological retinal neovascularization, a key factor in age-related macular degeneration (AMD). Demonstrated effective in mouse models, the vaccine offers a less invasive alternative to current intraocular therapies requiring repeated injections. This innovation could transform AMD treatment by reducing patient burden and providing durable disease control.